- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07372079
Neoadjuvant terapi for tidlig trippel-negativ brystkreft: En responsstyrt tilnærming ved bruk av Iparomlimab og Tuvonralimab-injeksjon i kombinasjon med kjemoterapi
Neoadjuvant terapi for tidlig trippelnegativ brystkreft: En responsveiledet tilnærming med iparomlimab og tuvonralimab-injeksjon i kombinasjon med kjemoterapi
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage breast-cancer patients to receive neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive four additional AC cycles before surgery. A key feature is the incorporation of an response-guided neoadjuvant therapy(RGN)model to identify sensitive patients who can forgo anthracyclines, thereby reducing long-term cardiotoxicity.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Yongsheng Jia, Doctor
- Telefonnummer: +86 18622199359
- E-post: yongshengjia@tjmuch.com
Studer Kontakt Backup
- Navn: Wenxiao Liu
- Telefonnummer: +86 18515456035
- E-post: liuwenxiao2016@outlook.com
Studiesteder
-
-
-
Tianjin, Kina
- Rekruttering
- Tianjin Medical University Cancer Institute & Hospital
-
Ta kontakt med:
- Yongsheng Jia, Doctor
- Telefonnummer: +86 18622199359
- E-post: yongshengjia@tjmuch.com
-
Ta kontakt med:
- Jun Zhang, doctor
- E-post: doctorjunzhang@163.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Voluntarily join this study, sign the informed consent form, and demonstrate good compliance;
- Age: 18-75 years old (at the time of signing the informed consent form);
- ECOG PS score: 0-1; expected survival time exceeding 6 months;
- Patients with primary breast cancer confirmed by histopathological or cytological examination;
- Primary tumor diameter > 2 cm as measured by local standard assessment methods;
- Judged by the investigator to meet the American Joint Committee on Cancer (AJCC) 8th edition breast cancer TNM staging criteria as cT2-cT4, cN0-cN3, cM0, with locally advanced or early-stage, unilateral, and histologically confirmed invasive breast cancer;
- According to the latest ASCO/CAP guideline definitions, histopathologically confirmed early-stage triple-negative invasive breast carcinoma meeting all of the following criteria:Tumors are triple-negative on pathological subtyping, defined as: ER-negative: IHC ≤10%; PR-negative: IHC ≤10%; HER2-negative: IHC 0/1+, or IHC 2+ with negative ISH.
- At least one measurable lesion according to RECIST 1.1;
- The patient agrees to undergo breast cancer resection surgery when meeting the surgical criteria after neoadjuvant therapy;
- PD-L1 expression status is known;
- Major organ functions are in good condition;
- Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. If a female subject of childbearing potential engages in sexual activity with a non-sterilized male partner, the subject must use acceptable and effective contraception from screening onward and agree to continue these precautions until 12 months after the last dose of the study drug; periodic abstinence and rhythm methods are not acceptable contraceptive methods.
- The subject is willing to provide core needle biopsy tissue samples for research analysis.
Exclusion Criteria:
- Patients with stage IV metastatic breast cancer or other patients deemed by the investigator as unable to achieve curative surgical resection through neoadjuvant therapy;
- Patients with inflammatory breast cancer;
- Patients who have had or currently have other malignancies within the past 3 years. The following two conditions may be eligible: other malignancies treated with a single surgical procedure, achieving continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)];
- Breast cancer patients who have received antitumor therapies such as chemotherapy, endocrine therapy, or immune checkpoint inhibitors within the past 3 years, or who have undergone breast surgery (except diagnostic biopsy for primary breast cancer);
- Patients who have undergone major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of study treatment (except diagnostic biopsy for primary breast cancer);
- Presence of any active autoimmune disease or a history of autoimmune disease;
- Patients currently using immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (at a dose >10 mg/day prednisone or equivalent steroids) and continuing such treatment within 2 weeks prior to enrollment;
- Allergy to any study drug or any component or excipient of the drug;
- Patients with concomitant diseases judged by the investigator as seriously endangering the subject's safety or affecting study completion, or those deemed unsuitable for enrollment for other reasons.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: QL1706 Combination Therapy
neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). |
Participants receive QL1706 every 3 weeks (Q3W) + Albumin-bound paclitaxel every 3 weeks (Q3W) + Cisplatin (Q3W) x 4 cycles. After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive QL1706 Q3W + epirubicin Q3W + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy before surgery. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
tpCR (ypT0/is ypN0)
Tidsramme: Opptil omtrent 27–30 uker
|
Opptil omtrent 27–30 uker
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Radiologisk fullstendig responsrate (iCR)
Tidsramme: Opptil omtrent 27–30 uker
|
Opptil omtrent 27–30 uker
|
|
bruksrate for epirubicin-cyclophosphamide-regimet
Tidsramme: Opptil ca. 16 uker
|
Opptil ca. 16 uker
|
|
Hendelsesfri overlevelse (EFS) som vurdert av undersøker
Tidsramme: Opptil omtrent 8 år
|
Opptil omtrent 8 år
|
|
Prosentandel av deltakere som opplever en uønsket hendelse (AE)
Tidsramme: Opptil omtrent 60 uker
|
Opptil omtrent 60 uker
|
|
Total overlevelse (OS)
Tidsramme: Opptil omtrent 8 år
|
Opptil omtrent 8 år
|
|
Helse-relatert livskvalitet (HR-QoL) poengsum
Tidsramme: Opptil omtrent 27–30 uker
|
Opptil omtrent 27–30 uker
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Yongsheng Jia, Tianjin Medical University Cancer Institute and Hospital
- Hovedetterforsker: Jun Zhang, Tianjin Medical University Cancer Institute and Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- E20251311
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .